Literature DB >> 9858081

Antidepressants and suicide mortality.

A Ohberg1, E Vuori, T Klaukka, J Lonnqvist.   

Abstract

BACKGROUND: This paper presents a nationwide analysis of suicide mortality in Finland from 1990 to 1995, when the total use of antidepressants, especially that by selective serotonin reuptake inhibitors (SSRIs) expanded in the country.
METHODS: Suicide rate was analysed by various methods including that by intake of antidepressants. Various antidepressants were compared by calculating fatal toxicity indices (FTI) by relating number of fatal poisonings by a drug to its consumption.
RESULTS: The expanded use of antidepressants coincided with an increased number of deaths caused by these drugs. The proportion of suicides committed by use of antidepressants among all suicides increased from 5.6% to 8.4%. The total suicide rate, however, declined significantly. This was mainly accounted for by the reduced suicide rates by hanging and carbomonoxide poisoning, which outnumbered the increased figures of suicides by poisoning. On the whole, 82% of suicides by antidepressants were committed by use of tricyclics. Use of doxepin and amitriptyline remained steady, and their FTIs were constantly high. The lowest FTIs were associated with fluoxetine, citalopram, mianserin and moclobemide. LIMITATIONS: The method ignores causality between the increased use of SSRIs and suicide mortality. Various factors affecting risk of suicide or choice of a method remain outside the scope of the data.
CONCLUSION: The increased use of SSRIs coincided with a significant decline in suicide mortality. However, suicides by use of antidepressants showed an upward trend. Therefore, in suicide prevention, risks and benefits of antidepressants should be considered in choosing treatment for depressive patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858081     DOI: 10.1016/s0165-0327(98)00114-1

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  11 in total

Review 1.  Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned?

Authors:  Robert D Gibbons; J John Mann
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

Review 2.  Suicidality with selective serotonin reuptake inhibitors: Valid claim?

Authors:  Yvon D Lapierre
Journal:  J Psychiatry Neurosci       Date:  2003-09       Impact factor: 6.186

3.  Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data.

Authors:  Anna Koski; Erkki Vuori; Ilkka Ojanperä
Journal:  Int J Legal Med       Date:  2005-03-01       Impact factor: 2.686

4.  News coverage of FDA warnings on pediatric antidepressant use and suicidality.

Authors:  Colleen L Barry; Susan H Busch
Journal:  Pediatrics       Date:  2009-12-07       Impact factor: 7.124

5.  Depression, suicidality and antidepressants: A coincidence?

Authors:  Vithyalakshmi Selvaraj; Snehamala Veeravalli; Sriram Ramaswamy; Richard Balon; Vikram K Yeragani
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

Review 6.  Use of selective serotonin reuptake inhibitors in children and adolescents.

Authors:  Ian C K Wong; Frank M C Besag; Paramala J Santosh; Macey L Murray
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 7.  Suicidal behaviour in bipolar disorder: risk and prevention.

Authors:  Leonardo Tondo; Göran Isacsson; Ross Baldessarini
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 8.  Post-approval drug safety surveillance.

Authors:  Robert D Gibbons; Anup K Amatya; C Hendricks Brown; Kwan Hur; Sue M Marcus; Dulal K Bhaumik; J John Mann
Journal:  Annu Rev Public Health       Date:  2010       Impact factor: 21.981

9.  Association between mortality from suicide in England and antidepressant prescribing: an ecological study.

Authors:  Oliver W C Morgan; Clare Griffiths; Azeem Majeed
Journal:  BMC Public Health       Date:  2004-12-21       Impact factor: 3.295

10.  Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial.

Authors:  Nader Perroud; Rudolf Uher; Andrej Marusic; Marcella Rietschel; Ole Mors; Neven Henigsberg; Joanna Hauser; Wolfgang Maier; Daniel Souery; Anna Placentino; Aleksandra Szczepankiewicz; Lisbeth Jorgensen; Jana Strohmaier; Astrid Zobel; Caterina Giovannini; Amanda Elkin; Cerisse Gunasinghe; Joanna Gray; Desmond Campbell; Bhanu Gupta; Anne E Farmer; Peter McGuffin; Katherine J Aitchison
Journal:  BMC Med       Date:  2009-10-15       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.